Suchergebnisse - "Skin Neoplasms/mortality"

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

Autoren: Saskia de Groot Hedwig M. Blommestein Brenda Leeneman et al.

Weitere Verfasser: Saskia de Groot Hedwig M. Blommestein Brenda Leeneman et al.

Quelle: Med Decis Making
Medical Decision Making, 45, 3, pp. 302-317

Schlagwörter: Proto-Oncogene Proteins B-raf, Decision Support Techniques, COST-EFFECTIVENESS, SDG 3 - Good Health and Well-being, Original Research Articles, Proto-Oncogene Proteins B-raf/genetics, Journal Article, BRAF plus MEK inhibitors, METASTATIC MELANOMA, Humans, Melanoma/drug therapy, Skin Neoplasms/mortality, Medical Oncology - Radboud University Medical Center, Melanoma, treatment sequences, immunotherapies, Advanced melanoma, Prognosis, Markov Chains, Treatment Outcome, Mutation, SURVIVAL, Disease Progression, decision model, semi-Markov, REAL-WORLD

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39985400
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/317779
https://doi.org/10.1177/0272989X251319338
https://pure.eur.nl/en/publications/d251aa20-b9d9-4558-8a6d-1e3132efcf5f
https://doi.org/10.1177/0272989X251319338
https://research.rug.nl/en/publications/78b43b9d-b315-43b7-860a-00f5bf5a2ef7
https://hdl.handle.net/11370/78b43b9d-b315-43b7-860a-00f5bf5a2ef7
https://doi.org/10.1177/0272989X251319338
https://cris.maastrichtuniversity.nl/en/publications/dec7d975-1de4-4147-b028-58c982e4f704
https://doi.org/10.1177/0272989X251319338
https://dspace.library.uu.nl/handle/1874/461022
https://hdl.handle.net/2066/317779
https://repository.ubn.ru.nl//bitstream/handle/2066/317779/317779.pdf

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study

Autoren: Mark Schuiveling Laurens S Ter Maat Isabella A J Van Duin et al.

Quelle: J Natl Cancer Inst
Journal of the National Cancer Institute, 117, 6, pp. 1245-1252
Journal of the National Cancer Institute, vol. 117, no. 6, pp. 1245-1252

Schlagwörter: Humans, Melanoma/drug therapy, Melanoma/mortality, Melanoma/pathology, Male, Female, Immune Checkpoint Inhibitors/therapeutic use, Body Composition, Middle Aged, Aged, Body Mass Index, Retrospective Studies, Tomography, X-Ray Computed, Adult, Treatment Outcome, Progression-Free Survival, Aged, 80 and over, Netherlands/epidemiology, Skin Neoplasms/drug therapy, Skin Neoplasms/mortality, Skin Neoplasms/pathology, Intra-Abdominal Fat, Muscle, Skeletal/diagnostic imaging, Subcutaneous Fat, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Medical Oncology - Radboud University Medical Center, Article

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39980388
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/320183
https://doi.org/10.1093/jnci/djaf039
https://repository.ubn.ru.nl//bitstream/handle/2066/320183/320183.pdf
https://hdl.handle.net/2066/320183
https://serval.unil.ch/notice/serval:BIB_3415CBA985BE
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3415CBA985BE8
https://serval.unil.ch/resource/serval:BIB_3415CBA985BE.P001/REF.pdf

Paediatric-onset lymphomatoid papulosis: results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG): results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)

Autoren: Blanchard, Mael Morren, Marie-Anne Busschots, Anne-Marie et al.

Weitere Verfasser: Blanchard, Mael Morren, Marie-Anne Busschots, Anne-Marie et al.

Quelle: The British journal of dermatology, vol. 191, no. 2, pp. 233-242

Schlagwörter: Male, Skin Neoplasms, Diagnostic Errors / statistics & numerical data, LYMPHOPROLIFERATIVE DISORDERS, CHILDHOOD, Molluscum Contagiosum / epidemiology, CHILDREN, Molluscum Contagiosum / pathology, RECOMMENDATIONS, Pityriasis Lichenoides, Pityriasis Lichenoides / epidemiology, Age of Onset, Child, 2. Zero hunger, Humans, Lymphomatoid Papulosis/pathology, Lymphomatoid Papulosis/epidemiology, Retrospective Studies, Female, Adolescent, Child, Preschool, Infant, Skin Neoplasms/pathology, Skin Neoplasms/epidemiology, Skin Neoplasms/mortality, Prognosis, Diagnostic Errors/statistics & numerical data, Pityriasis Lichenoides/epidemiology, Pityriasis Lichenoides/pathology, Pityriasis Lichenoides/diagnosis, Insect Bites and Stings/epidemiology, Insect Bites and Stings/complications, Molluscum Contagiosum/epidemiology, Molluscum Contagiosum/pathology, Molluscum Contagiosum/diagnosis, MYCOSIS-FUNGOIDES, 3. Good health, Skin Neoplasms / epidemiology, Life Sciences & Biomedicine, Insect Bites and Stings / complications, CLINICALLY BENIGN, Lymphomatoid Papulosis / pathology, Lymphomatoid Papulosis / epidemiology, Molluscum Contagiosum, Insect Bites and Stings / epidemiology, Dermatology, DIAGNOSIS, CLASSIFICATION, Pityriasis Lichenoides / pathology, MALIGNANCIES, LARGE-CELL LYMPHOMA, OMALIZUMAB, Lymphomatoid Papulosis, 1112 Oncology and Carcinogenesis, Diagnostic Errors, Molluscum Contagiosum / diagnosis, Skin Neoplasms / pathology, Science & Technology, Dermatology & Venereal Diseases, BENRALIZUMAB, EOSINOPHILS, 3202 Clinical sciences, Insect Bites and Stings, 1103 Clinical Sciences, Skin Neoplasms / mortality, Pityriasis Lichenoides / diagnosis, CHRONIC SPONTANEOUS URTICARIA

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38595050
https://hdl.handle.net/1887/4197261
https://archive-ouverte.unige.ch/unige:183445
https://doi.org/10.1093/bjd/ljae150
https://resolver.sub.uni-goettingen.de/purl?gro-2/143227
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4B285B4FA5832
https://serval.unil.ch/resource/serval:BIB_4B285B4FA583.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_4B285B4FA583

Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?

Autoren: Nielsen, Jesper Bo Kristiansen, Ivar Sønbø Thapa, Subash

Quelle: British Journal of Dermatology. 191:365-374

Schlagwörter: Male, Adult, Skin Neoplasms, Melanoma/mortality, Overdiagnosis, Adolescent, Ultraviolet Rays, Denmark, Biopsy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Ultraviolet Rays/adverse effects, Humans, Skin Neoplasms/mortality, Registries, Child, Melanoma, Aged, Incidence, Registries/statistics & numerical data, Middle Aged, Denmark/epidemiology, Overdiagnosis/statistics & numerical data, Sunlight/adverse effects, Sunlight, Female

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38655629

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma:Comparison of 3-year data from PRADO and OpACIN-neo

Autoren: Reijers, Irene L M Menzies, Alexander M Lopez-Yurda, Marta et al.

Quelle: Reijers, I L M, Menzies, A M, Lopez-Yurda, M, Versluis, J M, Rozeman, E A, Saw, R P M, van Houdt, W J, Kapiteijn, E, van der Veldt, A A M, Suijkerbuijk, K P M, Eriksson, H, Hospers, G A P, Klop, W M C, Torres Acosta, A, Grijpink-Ongering, L, Gonzalez, M, van der Wal, A, Al-Mamgani, A, Spillane, A J, Scolyer, R A, van de Wiel, B A, van Akkooi, A C J, Long, G V & Blank, C U 2025, 'Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma ....

Schlagwörter: Humans, Melanoma/mortality, Neoadjuvant Therapy/mortality, Male, Female, Middle Aged, Neoplasm Staging, Ipilimumab/therapeutic use, Aged, Chemotherapy, Adjuvant, Skin Neoplasms/mortality, Lymph Node Excision, Immune Checkpoint Inhibitors/therapeutic use, Adult, Immunotherapy/methods, Nivolumab/therapeutic use, Precision Medicine/methods, Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Dateibeschreibung: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39602990; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c; info:eu-repo/semantics/altIdentifier/pissn/0959-8049; info:eu-repo/semantics/altIdentifier/eissn/1879-0852

Verfügbarkeit: https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://research.rug.nl/en/publications/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://doi.org/10.1016/j.ejca.2024.115141
https://pure.rug.nl/ws/files/1277673260/1-s2.0-S0959804924017489-main.pdf
https://www.scopus.com/pages/publications/85210014804

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

Autoren: de Groot, Saskia Blommestein, Hedwig M Leeneman, Brenda et al.

Weitere Verfasser: de Groot, Saskia Blommestein, Hedwig M Leeneman, Brenda et al.

Schlagwörter: Melanoma/drug therapy, Humans, Proto-Oncogene Proteins B-raf/genetics, Decision Support Techniques, Markov Chains, Disease Progression, Prognosis, Mutation, Skin Neoplasms/mortality, Journal Article

Dateibeschreibung: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/461022

Verfügbarkeit: https://dspace.library.uu.nl/handle/1874/461022

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma

Autoren: Jeffrey Weber Waqas Haque Svetomir N Markovic et al.

Quelle: Oncologist
The oncologist, vol. 30, no. 3

Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, Humans, Oximes/administration & dosage, Oximes/therapeutic use, Oximes/pharmacology, Melanoma/drug therapy, Melanoma/genetics, Melanoma/pathology, Melanoma/mortality, Male, Female, Middle Aged, Imidazoles/therapeutic use, Imidazoles/administration & dosage, Imidazoles/pharmacology, Proto-Oncogene Proteins B-raf/genetics, Pyrimidinones/administration & dosage, Pyrimidinones/therapeutic use, Pyrimidinones/pharmacology, Pyridones/administration & dosage, Pyridones/therapeutic use, Pyridones/pharmacology, Retrospective Studies, Adult, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Chemotherapy, Adjuvant/methods, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Skin Neoplasms/genetics, Skin Neoplasms/mortality, Mutation, Disease-Free Survival, BRAF mutation, dabrafenib, melanoma, relapse-free survival, trametinib, Melanoma and Cutaneous Malignancies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39560953
https://serval.unil.ch/notice/serval:BIB_A8A26871D41B
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A8A26871D41B1
https://serval.unil.ch/resource/serval:BIB_A8A26871D41B.P001/REF.pdf

Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis

Autoren: Tønder, Jens Ejrnæs Bønnelykke-Behrndtz, Marie Louise Laurberg, Tinne et al.

Quelle: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Tønder, J E, Bønnelykke-Behrndtz, M L, Laurberg, T, Røssell, E-L & Sollie, M 2024, 'Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes : a systematic review and meta-analysis', BMC Cancer, vol. 24, 812. https://doi.org/10.1186/s12885-024-12598-8

Schlagwörter: Skin Neoplasms, Melanoma/mortality, Diabetes Mellitus, Type 2/complications, Incidence, Diabetes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Type 2 diabetes, 3. Good health, Meta-analysis, Diabetes Mellitus, Type 2, Risk Factors, Systematic review, Humans, Skin Neoplasms/mortality, Systematic Review, Melanoma, RC254-282, Cancer, Neoplasm Staging

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38972968
https://doaj.org/article/22b4698b8252480398d0aecbcfadacc7

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Autoren: A. Gawaz I. Wolff L. Nanz et al.

Quelle: Cancer Immunol Immunother

Schlagwörter: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial).

Autoren: De Smedt, Julie Van Kelst, Sofie Janssen, Laudine et al.

Quelle: British Journal of Dermatology, 191 (6), 886 - 896 (2024-11-18)

Schlagwörter: Vitamin D, 25-hydroxyvitamin D, Cholecalciferol, Vitamins, Humans, Female, Male, Double-Blind Method, Middle Aged, Aged, Adult, Prospective Studies, Cholecalciferol/administration & dosage, Cholecalciferol/adverse effects, Treatment Outcome, Neoplasm Recurrence, Local/prevention & control, Neoplasm Recurrence, Local/epidemiology, Vitamins/administration & dosage, Melanoma/mortality, Melanoma/drug therapy, Skin Neoplasms/mortality, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Vitamin D/administration & dosage, Vitamin D/blood, Vitamin D/analogs & derivatives, Dietary Supplements, Melanoma, Neoplasm Recurrence, Local, Skin Neoplasms, Dermatology, Human health sciences, Sciences de la santé humaine, Dermatologie

Relation: https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae257/58941454/ljae257.pdf; urn:issn:0007-0963; urn:issn:1365-2133

Zugangs-URL: https://orbi.uliege.be/handle/2268/335730

Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG 'PARCT'

Autoren: Rudolf Stadler Gabriele Roccuzzo Pablo Ortiz-Romero et al.

Quelle: European journal of cancer, vol. 222, pp. 115484

Schlagwörter: Anti-PD-L1, Atezolizumab, Clinical trial number, Cutaneous lymphoma, EORTC-1652-CLTG, EudraCT Number 2017–003680-35, Mycosis fungoides, NCT03357224, Sézary syndrome, Humans, Mycosis Fungoides/drug therapy, Mycosis Fungoides/pathology, Mycosis Fungoides/mortality, Mycosis Fungoides/immunology, Male, Female, Sezary Syndrome/drug therapy, Sezary Syndrome/pathology, Sezary Syndrome/mortality, Sezary Syndrome/immunology, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/adverse effects, Middle Aged, Aged, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Skin Neoplasms/mortality, Skin Neoplasms/immunology, Adult, Immune Checkpoint Inhibitors/therapeutic use, Immune Checkpoint Inhibitors/adverse effects, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Aged, 80 and over, Progression-Free Survival, B7-H1 Antigen/antagonists & inhibitors, Sézary syndrome

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40319676
https://serval.unil.ch/resource/serval:BIB_D7489099ACC0.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_D7489099ACC0
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_D7489099ACC05
https://pergamos.lib.uoa.gr/uoa/dl/object/3494077

International melanoma and non melanoma skin cancer mortality trends: is it time to refocus our attention?

Autoren: Zoe C Venables Sonia Gran Nick J Levell et al.

Quelle: Venables, Z C, Gran, S, Levell, N J, Yiu, Z Z N & Proby, C M 2024, 'International melanoma and non-melanoma skin cancer mortality trends-is it time to re-focus our attention?', Clinical and Experimental Dermatology, vol. 49, no. 5, pp. 514-516. https://doi.org/10.1093/ced/llad438

Schlagwörter: Global Health/statistics & numerical data, Male, Skin Neoplasms, Melanoma/mortality, Humans, Female, Skin Neoplasms/mortality, Mortality, Mortality/trends, Global Health, Melanoma, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38060677

Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

Autoren: Miriam Mengoni Andreas Dominik Braun Mattes Simon Hinnerichs et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Middle Aged, Prognosis, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Body Composition, Humans, Female, Muscle, Skeletal, Tomography, X-Ray Computed, Melanoma, Immune Checkpoint Inhibitors, Melanoma/therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Muscle, Skeletal/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Low skeletal muscle mass, Tomography, X-Ray Computed [MeSH], Male [MeSH], Muscle, Skeletal/pathology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Body Composition [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Immunotherapy, Prognosis [MeSH], Skin Neoplasms/mortality [MeSH], Body composition, Retrospective Studies, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38796605
https://repository.publisso.de/resource/frl:6492801

Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study

Autoren: Juliette Renaud Bianca F. Goemans Franco Locatelli et al.

Quelle: Pediatric blood & cancer, vol. 71, no. 7, pp. e31006
Renaud, Juliette; Goemans, Bianca F; Locatelli, Franco; Pigazzi, Martina; Redmond, Shelagh; Kuehni, Claudia E; Destaillats, Alice; Alonzo, Todd A; Gerbing, Robert B; Gamis, Alan; Aplenc, Richard; Renella, Raffaele; Cooper, Todd; Ceppi, Francesco (2024). Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study. Pediatric blood & cancer, 71(7), e31006. Wiley 10.1002/pbc.31006 <http://dx.doi.org/10.1002/pbc.31006>

Schlagwörter: Male, Skin Neoplasms, Infant, Newborn, Infant, 610 Medicine & health, Prognosis, 3. Good health, Survival Rate, Leukemia, Myeloid, Acute, 360 Social problems & social services, Humans, Female, Retrospective Studies, Leukemia, Myeloid, Acute/mortality, Leukemia, Myeloid, Acute/pathology, Leukemia, Myeloid, Acute/genetics, Leukemia, Myeloid, Acute/therapy, Skin Neoplasms/pathology, Skin Neoplasms/mortality, Skin Neoplasms/therapy, Skin Neoplasms/genetics, Follow-Up Studies, acute myeloid leukemia, aleukemic leukemia cutis, cutaneous infiltration, extramedullary disease, infants

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38616361
https://serval.unil.ch/resource/serval:BIB_CCB2557653E6.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_CCB2557653E65
https://serval.unil.ch/notice/serval:BIB_CCB2557653E6
https://boris.unibe.ch/195984/

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Autoren: Verheijden, R.J. Burgers, F.H. Janssen, J.C. et al.

Quelle: European journal of cancer, vol. 207, pp. 114172

Schlagwörter: Humans, Male, Female, Melanoma/drug therapy, Melanoma/immunology, Melanoma/mortality, Immunosuppressive Agents/adverse effects, Immunosuppressive Agents/therapeutic use, Immune Checkpoint Inhibitors/adverse effects, Middle Aged, Aged, Adrenal Cortex Hormones/therapeutic use, Adrenal Cortex Hormones/adverse effects, Adult, Retrospective Studies, Skin Neoplasms/drug therapy, Skin Neoplasms/immunology, Skin Neoplasms/mortality, 80 and over, Checkpoint inhibitor, Corticosteroids, Immune-related adverse events, Immunosuppression, Melanoma, Toxicity

Dateibeschreibung: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/38905818; info:eu-repo/semantics/altIdentifier/eissn/1879-0852; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AB4D3ADF8F4A8; https://serval.unil.ch/notice/serval:BIB_AB4D3ADF8F4A; https://serval.unil.ch/resource/serval:BIB_AB4D3ADF8F4A.P001/REF.pdf

Verfügbarkeit: https://serval.unil.ch/notice/serval:BIB_AB4D3ADF8F4A
https://doi.org/10.1016/j.ejca.2024.114172
https://serval.unil.ch/resource/serval:BIB_AB4D3ADF8F4A.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_AB4D3ADF8F4A8

Paediatric-onset lymphomatoid papulosis : results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)

Autoren: Blanchard, Maël Morren, Marie-Anne Busschots, Anne-Marie et al.

Quelle: ISSN: 0007-0963 ; British journal of dermatology, vol. 191, no. 2 (2024) p. 233-242.

Schlagwörter: info:eu-repo/classification/ddc/616, Humans, Lymphomatoid Papulosis / pathology, Lymphomatoid Papulosis / epidemiology, Male, Retrospective Studies, Child, Female, Adolescent, Preschool, Infant, Skin Neoplasms / pathology, Skin Neoplasms / epidemiology, Skin Neoplasms / mortality, Age of Onset, Prognosis, Diagnostic Errors / statistics & numerical data, Pityriasis Lichenoides / epidemiology, Pityriasis Lichenoides / pathology, Pityriasis Lichenoides / diagnosis, Insect Bites and Stings / epidemiology, Insect Bites and Stings / complications, Molluscum Contagiosum / epidemiology, Molluscum Contagiosum / pathology, Molluscum Contagiosum / diagnosis

Relation: info:eu-repo/semantics/altIdentifier/pmid/38595050; unige:183445

Verfügbarkeit: https://archive-ouverte.unige.ch/unige:183445

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial: health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Autoren: Bottomley A. Coens C. Mierzynska J. et al.

Weitere Verfasser: Bottomley A. Coens C. Mierzynska J. et al.

Quelle: EORTC Melanoma Group 2021, 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial', The Lancet Oncology, vol. 22, no. 5, pp. 655-664. https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 5, pp. 655-664
Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664
EORTC Melanoma Group 2021, 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial', The Lancet Oncology, vol. 22, no. 5, pp. 655-664. https://doi.org/10.1016/S1470-2045(21)00081-4

Schlagwörter: Adult, Male, Melanoma / psychology, Skin Neoplasms / psychology, Skin Neoplasms, Antibodies, Monoclonal, Humanized / therapeutic use, Humanized/therapeutic use, Medizin, Skin Neoplasms / drug therapy, Antibodies, Monoclonal, Humanized, Antibodies, Melanoma / mortality, 03 medical and health sciences, Melanoma / pathology, Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Monoclonal, Skin Neoplasms/drug therapy, 80 and over, Humans, Melanoma/drug therapy, Skin Neoplasm, Middle aged, Humanized, Melanoma, Aged, Neoplasm Staging, ddc:616, Aged, 80 and over, Skin Neoplasms / pathology, Melanoma / drug therapy, Manchester Cancer Research Centre, Quality of Life, Humans [MeSH], Oncology and carcinogenesis, Middle Aged, Skin Neoplasms / mortality, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Antibodies, Monoclonal, Humanized/therapeutic use, Female

Dateibeschreibung: application/pdf; STAMPA

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/33857414
https://research.manchester.ac.uk/en/publications/5f4dda20-295c-4eb2-8c2e-9f1e67d7f192
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.ncbi.nlm.nih.gov/pubmed/33857414
https://inrepo01.inet.dkfz-heidelberg.de/record/168977
https://findanexpert.unimelb.edu.au/scholarlywork/1518989-adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-%28eortc-1325-mg-keynote-054%29--health-related-quality-of-life-results-from-a-double-blind--randomised--controlled--phase-3-trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00081-4/fulltext
https://www.sciencedirect.com/science/article/pii/S1470204521000814
https://research.unipg.it/handle/11391/1492110
https://research.vumc.nl/en/publications/3a96aa01-a65e-4d39-b2e9-0c87a44be567
https://archive-ouverte.unige.ch/unige:159804
https://www.sciencedirect.com/science/article/pii/S1470204521000814
https://doi.org/10.1016/S1470-2045(21)00081-4
https://hdl.handle.net/11365/1233297
https://hdl.handle.net/11391/1492110
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.ncbi.nlm.nih.gov/pubmed/33857414
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85105831665
https://pure.rug.nl/ws/files/358617018/PIIS1470204521000814.pdf

Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma

Autoren: Laura Susok Thilo Gambichler

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Adult, Male, Skin Neoplasms, Adolescent, Original Article – Clinical Oncology, White People, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Germany, Humans, 10. No inequality, Melanoma, Aged, 80 and over [MeSH], Aged [MeSH], Skin Neoplasms/ethnology [MeSH], Whites/statistics, Extremities/pathology [MeSH], Germany/epidemiology [MeSH], Cohort Studies [MeSH], Neoplasm Staging [MeSH], Male [MeSH], Melanoma/pathology [MeSH], Superficial spreading melanoma, Case-Control Studies [MeSH], Progosis, Melanoma/diagnosis [MeSH], Adolescent [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Humans [MeSH], Overall survival, Survival Analysis [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Prognosis [MeSH], Young Adult [MeSH], Skin Neoplasms/mortality [MeSH], Acral lentiginous melanoma, Melanoma/ethnology [MeSH], Skin Neoplasms/diagnosis [MeSH], Aged, Neoplasm Staging, Aged, 80 and over, ddc:610, Extremities, Middle Aged, Prognosis, Survival Analysis, 3. Good health, Case-Control Studies, Female, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03630-6.pdf
https://pubmed.ncbi.nlm.nih.gov/33856527
https://link.springer.com/article/10.1007/s00432-021-03630-6
https://www.ncbi.nlm.nih.gov/pubmed/33856527
http://europepmc.org/article/MED/33856527
https://link.springer.com/content/pdf/10.1007/s00432-021-03630-6.pdf
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/9784
https://nbn-resolving.org/urn:nbn:de:hbz:294-97841
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/9784/GambichlerThilo15042021.pdf
https://repository.publisso.de/resource/frl:6449884

Skin melanoma deaths within 1 or 3 years from diagnosis in Europe

Autoren: Jaume Galceran Christine Bouchardy Elizabeth Van Eycken et al.

Quelle: International journal of cancer, Vol. 148, No 12 (2021) pp. 2898-2905

Schlagwörter: Adult, Male, Skin Neoplasms, Adolescent, Prognostic factors, Mortality / trends, Skin Neoplasms / diagnosis, Melanoma / mortality, Young Adult, 03 medical and health sciences, Melanoma / pathology, 0302 clinical medicine, Humans, Registries, Mortality, Child, Melanoma, ddc:613, Aged, Skin Neoplasms / pathology, Sex Characteristics, Lethality, Incidence, Age Factors, Infant, Newborn, Infant, Middle Aged, Melanoma / diagnosis, Skin Neoplasms / mortality, 3. Good health, Europe, Child, Preschool, Multivariate Analysis, Female, Trends, Europe / epidemiology

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/33497469
https://www.ncbi.nlm.nih.gov/pubmed/33497469
http://www.ncbi.nlm.nih.gov/pubmed/33497469
https://pubmed.ncbi.nlm.nih.gov/33497469/
https://europepmc.org/article/MED/33497469
https://archive-ouverte.unige.ch/unige:155405
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33479
https://archive-ouverte.unige.ch/unige:155405

Slow Mohs Micrographic Surgery for Acral Melanoma Treatment in Korean Patients

Autoren: Sang Kyum Kim Yeongjoo Oh Mi Ryung Roh et al.

Weitere Verfasser: Sang Kyum Kim Yeongjoo Oh Mi Ryung Roh et al.

Quelle: Dermatologic Surgery. 47:e42-e46

Schlagwörter: Adult, Male, Skin Neoplasms, Local / epidemiology, Skin Neoplasms / diagnosis, Disease-Free Survival, Melanoma / mortality, Melanoma / surgery, 03 medical and health sciences, Melanoma / pathology, 0302 clinical medicine, Skin Neoplasms / surgery, Republic of Korea, Local / prevention & control, Humans, Melanoma, Mohs Surgery / methods, Republic of Korea / epidemiology, Aged, Retrospective Studies, Skin, Skin Neoplasms / pathology, Skin / pathology, Foot, Margins of Excision, Torso, Middle Aged, Melanoma / diagnosis, Hand, Mohs Surgery, Skin Neoplasms / mortality, 3. Good health, Survival Rate, Neoplasm Recurrence, Local / pathology, Female, Neoplasm Recurrence, Local, Follow-Up Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/33481431
https://www.ncbi.nlm.nih.gov/pubmed/33481431
https://pubmed.ncbi.nlm.nih.gov/33481431/
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184146
https://yonsei.pure.elsevier.com/en/publications/slow-mohs-micrographic-surgery-for-acral-melanoma-treatment-in-ko
https://europepmc.org/article/MED/33481431
https://journals.lww.com/10.1097/DSS.0000000000002827